newsmetry
rusign inget started
macro

Analysts raise price targets for Genmab, Manhattan Associates, Pitney Bowes and Takeda

Average 12-month analyst price targets rose for four companies at once, according to TradingView data sourced from FactSet.

published on Newsmetry
original source published

the same feed is available to bots and dashboards through the api. connect the api →

Newsmetry newsroom

what happened

According to TradingView, citing FactSet, the average 12-month price target for Genmab A/S shares rose from $60.82 to $61.56. Estimates from 22 analysts range from $42 to $80, and based on the October 28 close the target implies roughly 7% potential upside. The consensus stays at “Buy” across 28 covering analysts, with 23 Buys, 2 Holds and 3 Sells.

For Manhattan Associates, the average target climbed from $267.4 to $271.4, with estimates from 10 analysts spanning $230 to $305. The implied upside is about 13% from the October 28 close, and 11 of the 15 covering analysts rate the stock a Buy.

Pitney Bowes saw its average target edge up from $19.56 to $19.72, with five analysts forecasting between $18 and $22, and its consensus remains “Hold.” Takeda’s average target rose from $20.81 to $21.05, implying about 4% upside, and its consensus stays at “Buy.”

why it matters

Small adjustments like these reflect where analysts currently stand and rarely move the broader market on their own. For investors they serve as a rough gauge of sentiment ahead of company-specific updates, but they do not signal where share prices are headed.

tags

Analyst RatingStockDenmarkUnited StatesJapan

instruments

Genmab A/SManhattan AssociatesPitney BowesTakeda Pharmaceutical

sources

  1. Genmab A/S Stock 12‑Month Price Target Raised to $61.56, Implies 7% Upside — TradingView, 29 October 2026 at 19:20 UTC
  2. Manhattan Associates, Inc. Stock 12‑Month Price Target Raised to $271.4, Implies 13% Upside — TradingView, 29 October 2026 at 19:20 UTC
  3. Pitney Bowes Inc. Stock 12‑Month Price Target Raised to $19.72, Implies 13% Upside — TradingView, 29 October 2026 at 19:20 UTC
  4. Takeda Pharmaceutical Company Limited Stock 12‑Month Price Target Raised to $21.05, Implies 4% Upside — TradingView, 29 October 2026 at 19:20 UTC

prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.

alerts on your topics, the morning digest and the api — in your account.

get stories in real time ↗

related stories